The use of SGLT-2 inhibitors in type 2 diabetes and heart failure

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 7, 2015, Pages 292-297

  Riggs, Kayla ^a   Ali, Hiba ^a   Taegtmeyer, Heinrich ^b   Gutierrez, Absalon D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANTIDIABETIC ACTIVITY; ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOTOXICITY; DIABETIC PATIENT; DISEASE ACTIVITY; DRUG MECHANISM; DRUG SAFETY; GLUCOTOXICITY; HEART FAILURE; HUMAN; KIDNEY FUNCTION; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIAC MUSCLE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; KIDNEY; METABOLISM; TREATMENT OUTCOME; URINARY EXCRETION; URINE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MYOCARDIUM; RENAL ELIMINATION; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84951921572     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0038     Document Type: Review

References (77)

1. Centers for Disease Control, and Prevention, Division of Diabetes Translation. National diabetes statistics report, 2014. Accessed at www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. March 23, 2015
2. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes, and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33: 562-568
3. Dei Cas A, Khan SS, Butler J, et al. Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC Heart Fail 2015; 3: 136-145
4. Rijzewijk LJ, Van Der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 1793-1799
5. Young ME, McNulty P, Taegtmeyer H. Adaptation, and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861-1870
6. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176
7. Taegtmeyer H, McNulty P, Young ME. Adaptation, and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002; 105: 1727-1733
8. Khalaf KI, Taegtmeyer H. After avandia: the use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J 2012; 39: 174-178
9. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance, and risk of congestive heart failure. JAMA 2005; 294: 334-341
10. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004; 18: 1692-1700
11. Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality, and Morbidity (CHARM) program. Diabetes Care 2009; 32: 915-920
12. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors, and cardiovascular risk: proposed pathways, and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12: 90-100
13. Taegtmeyer H, Hems R, Krebs HA. Utilization of energyproviding substrates in the isolated working rat heart. Biochem J 1980; 186: 701-711
14. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels, and mortality in patients with diabetes, and advanced systolic heart failure. Am Heart J 2006; 151: 191
15. Aguilar D, Bozkurt B, Ramasubbu K, et al. Relationship of hemoglobin A1C, and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54: 422-428
16. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality, and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75
17. Ekeruo IA, Solhpour A, Taegtmeyer H. Metformin in diabetic patients with heart failure: safe, and effective? Curr Cardiovasc Risk Rep 2013; 7: 417-422
18. Nasir S, Aguilar D. Congestive heart failure, and diabetes mellitus: balancing glycemic control with heart failure improvement. Am J Cardiol 2012; 110: 50B-57B
19. Braunwald E. Heart failure. JACC Heart Fail 2013; 1: 1-20
20. Chatterjee K. Pathophysiology of systolic, and diastolic heart failure. Med Clin North Am 2012; 96: 891-899
21. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789
22. Chiu HC, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107: 813-822
23. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-1231
24. Young ME, Guthrie PH, Razeghi P, et al. Impaired longchain fatty acid oxidation, and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002; 51: 2587-2595
25. Chiu HC, Kovacs A, Blanton RM, et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005; 96: 225-233
26. Drosatos K, Schulze PC. Cardiac lipotoxicity: molecular pathways, and therapeutic implications. Curr Heart Fail Rep 2013; 10: 109-121
27. Park SY, Cho YR, Kim HJ, et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs, and cardiac dysfunction in C57BL/6 mice. Diabetes 2005; 54: 3530-3540
28. Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes, and coronary artery disease with myocardial insulin resistance. Diabetes 2002; 51: 3020-3024
29. Mazumder PK, O Neill BT, Roberts MW, et al. Impaired cardiac efficiency, and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004; 53: 2366-2374
30. How OJ, Aasum E, Severson DL, et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55: 466-473
31. Belke DD, Larsen TS, Gibbs EM, et al. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000; 279: E1104-1113
32. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514
33. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508
34. Dewald O, Sharma S, Adrogue J, et al. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species, and prevents lipotoxicity. Circulation 2005; 112: 407-415
35. Park SY, Cho YR, Finck BN, et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptoralpha causes insulin resistance in heart, and liver. Diabetes 2005; 54: 2514-2524
36. Bjorkegren J, Veniant M, Kim SK, et al. Lipoprotein secretion, and triglyceride stores in the heart. J Biol Chem 2001; 276: 38511-38517
37. Yagyu H, Chen G, Yokoyama M, et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake, and produces a cardiomyopathy. J Clin Invest 2003; 111: 419-426
38. Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation, and leads to cardiomyopathy. Nat Med 2004; 10: 1245-1250
39. Nielsen LB, Bartels ED, Bollano E. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation, and development of cardiac dysfunction in diabetic mice. J Biol Chem 2002; 277: 27014-27020
40. Yokoyama M, Yagyu H, Hu Y, et al. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004; 279: 4204-4211
41. Korosoglou G, Humpert PM, Ahrens J, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging 2012; 35: 804-811
42. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116: 1170-1175
43. Utz W, Engeli S, Haufe S, et al. Myocardial steatosis, cardiac remodelling, and fitness in insulin-sensitive, and insulin-resistant obese women. Heart 2011; 97: 1585-1589
44. Kankaanpaa M, Lehto HR, Parkka JP, et al. Myocardial triglyceride content, and epicardial fat mass in human obesity: relationship to left ventricular function, and serum free fatty acid levels. J Clin Endocrinol Metab 2006; 91: 4689-4695
45. Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 2010; 53: 1331-1340
46. Krssak M, Winhofer Y, Gobl C, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia 2011; 54: 1871-1878
47. Winhofer Y, Krssak M, Jankovic D, et al. Short-term hyperinsulinemia, and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes 2012; 61: 1210-1216
48. Lindsey JB, Marso SP. Steatosis, and diastolic dysfunction: the skinny on myocardial fat. J Am Coll Cardiol 2008; 52: 1800-1802
49. Sen S, Kundu BK, Wu HC, et al. Glucose regulation of load-induced mTOR signaling, and ER stress in mammalian heart. J Am Heart Assoc 2013; 2: e004796
50. Teshima Y, Takahashi N, Saikawa T, et al. Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase, and ryanodine sensitive Ca(2+)Channel mRNA in streptozotocininduced diabetic rat heart. J Mol Cell Cardiol 2000; 32: 655-664
51. Gawlowski T, Stratmann B, Stork I, et al. Heat shock protein 27 modification is increased in the human diabetic failing heart. Horm Metab Res 2009; 41: 594-599
52. Brogard JM, Vetter T, Blickle JF. Discovery of pancreatic diabetes in Strasbourg. Diabete Metab 1992; 18: 104-114
53. Doram K, Bouland DL. Diabetes mellitus-new hope for an old disease. West J Med 1994; 160: 250-251
54. Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care 2014; 37: 3124-3131
55. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284
56. Lu Y, Griffen SC, Boulton DW, et al. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1, and SGLT2 in renal glucose reabsorption in humans. Front Pharmacol 2014; 5: 274
57. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21: 512-517
58. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031
59. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
60. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883
61. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight, and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159-169
62. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy, and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950
63. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin, and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700
64. Doenst T, Goodwin GW, Cedars AM, et al. Load-induced changes in vivo alter substrate fluxes, and insulin responsiveness of rat heart in vitro. Metabolism 2001; 50: 1083-1090
65. Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009; 119: 2568-2577
66. Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011; 60: 1770-1778
67. Younis FM, Hollander K, Mayoux EW, et al. Effect of prophylactic treatment of empagliflozin on cardiac function, and diabetes in CRDH rats. Diabetes 2014; 63: A273 (1056-P
68. Baker WL, Smyth LR, Riche DM, et al. Effects of sodiumglucose co-transporter 2 inhibitors on blood pressure: a systematic review, and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275
69. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review, and meta-analysis. Ann Intern Med 2013; 159: 262-274
70. Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862
71. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 1087-1095
72. Cooper JN, Buchanich JM, Youk A, et al. Reductions in arterial stiffness with weight loss in overweight, and obese young adults: potential mechanisms. Atherosclerosis 2012; 223: 485-490
73. Hughes TM, Althouse AD, Niemczyk NA, et al. Effects of weight loss, and insulin reduction on arterial stiffness in the SAVE trial. Cardiovasc Diabetol 2012; 11: 114
74. Oelze M, Kroller-Schon S, Welschof P, et al. The sodiumglucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress, and glucotoxicity. PLoS One 2014; 9: e112394
75. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness, and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28
76. El-Assaad W, Joly E, Barbeau A, et al. Glucolipotoxicity alters lipid partitioning, and causes mitochondrial dysfunction, cholesterol, and ceramide deposition, and reactive oxygen species production in INS832/13 ss-cells. Endocrinology 2010; 151: 3061-3073
77. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66-74